PrintCombination Oral Medicines
Brand Name (Generic Name)
Actoplus Met (pioglitazone metformin)
Warning: pioglitazone, which is a component of Actoplus Met, may be associated with an increased risk of bladder cancer in some patients after using Actos for more than one year. For more information on side effects, refer to the pioglitazone and metformin sections.
Avandamet (rosiglitazone maleate metformin hydrochloride)
Warning: rosiglitazone, which is a component of Avandamet, can cause or worsen congestive heart failure in some patients. Due to the side effects, Avandamet is now only available to patients who enroll in a special program. Talk to your doctor to get more information on the program. For more information on side effects, refer to the rosiglitazone and metformin sections.
Avandaryl (rosiglitazone glimepiride)
Duetact (pioglitazone glimepiride)
Glucovance (glyburide metformin hydrochloride)
For more information on side effects, refer to the glyburide and metformin sections.
Janumet (sitagliptin/metformin HCl)
For more information on side effects, see DPP-IV Inhibitors and biguanides.
Janumet XR (sitagliptin (Januvia) and metformin hydrochloride (HCl) extended-release) is a once-daily oral medication. For more information on side effects, see DPP-IV Inhibitors and biguanides.
Jentadueto (linagliptin/metformin hydrochloride) is a twice-daily oral medication.
For more information on side effects, see DPP-IV Inhibitors and biguanides.
Juvisync (sitagliptin and simvastatin)
For more information on side effects, see DPP-IV Inhibitors and Simvastatin.
Kazano (alogliptin/metformin)
Kombiglyze XR (saxagliptin/metformin)
Once-a-day metformin extended-release (XR) plus saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet. For more information, see DPP-IV Inhibitors and biguanides
Metaglip (glipizide metformin)
Oseni (alogliptin/pioglitazone)
PrandiMet (repaglinide metformin HCl tablets)
A meglitinides and biguanides combination drug approved for use as an adjunct to diet and exercise in type 2 diabetes patients when response to repaglinide or metformin monotherapy is inadequate.
Reviewed by James A. Bennett 5/13
You are subscribed!
You are subscribed!
You are subscribed!
Recipe Shuffle
This morning it wasn’t the sun, the wind, or the birds that woke me up. It was the soft, insistent vibrating of a medical device urging me to check my blood sugar. Opening my eyes, still safely under the covers, I checked my blood sugar with a meter smaller than a deck of cards, calibrated my continuous glucose monitor, and then glanced at my insulin pump — which reminded me that today was the day I needed to change my infusion set. My dLife is pretty high tech. And I’m...
